Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ocular Therapeutix (OCUL) Misses Q2 EPS by 33c, Revenues Beat
August 7, 2020 7:19 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.64), $0.33 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.57 million versus the consensus estimate of $1.5 million.
Despite the challenges caused by the global pandemic, it has been a very productive quarter for Ocular Therapeutix, said Antony Mattessich, President and CEO. Our clinical... More
